Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response
Jazyk angličtina Země Itálie Médium print-electronic
Typ dokumentu klinické zkoušky, časopisecké články
Grantová podpora
VEGA 1/0873/18
Agentúra na Podporu Výskumu a Vývoja
PubMed
32026157
DOI
10.1007/s10238-020-00612-9
PII: 10.1007/s10238-020-00612-9
Knihovny.cz E-zdroje
- Klíčová slova
- Apparent diffusion coefficient, Diffusion-weighted imaging, Early response, Imaging biomarker, MRI, Prediction, Progress, Renal cell carcinoma, Systemic treatment, Targeted therapy, Tyrosine kinase inhibitor,
- MeSH
- difuzní magnetická rezonance metody MeSH
- indazoly MeSH
- inhibitory angiogeneze terapeutické užití MeSH
- Kaplanův-Meierův odhad MeSH
- karcinom z renálních buněk diagnostické zobrazování farmakoterapie mortalita patologie MeSH
- ledviny diagnostické zobrazování MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory ledvin diagnostické zobrazování farmakoterapie mortalita patologie MeSH
- pyrimidiny terapeutické užití MeSH
- retrospektivní studie MeSH
- ROC křivka MeSH
- senioři MeSH
- sulfonamidy terapeutické užití MeSH
- výsledek terapie MeSH
- zdraví dobrovolníci pro lékařské studie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- Názvy látek
- indazoly MeSH
- inhibitory angiogeneze MeSH
- pazopanib MeSH Prohlížeč
- pyrimidiny MeSH
- sulfonamidy MeSH
Accurate prediction of early treatment response to systemic therapy (ST) with tyrosine kinase inhibitors (TKI) in patients with metastatic renal cell carcinoma (mRCC) could help avoid ineffective and expensive treatment with serious side effects. Neither RECIST v.1.1 nor Choi criteria successfully discriminate between patients with mRCC who received ST having a short or long time to progression (TTP). There is no biomarker, which is able to predict early therapeutic response to TKIs application in patients with mRCC. The goal of our study was to investigate the potential of apparent diffusion coefficient (ADC) of diffusion-weighted imaging (DWI) of MRI in prediction of early therapeutic response to ST with pazopanib in patients with mRCC. The retrospective study enrolled 32 adult patients with conventional mRCC who received pazopanib (mean duration-7.5 ± 3.45). The mean duration of follow-up was 11.85 ± 4.34 months. In all patients as baseline examination and 1 month after treatment, 1.5T MRI including DWI sequence was performed followed by ADC measurement of the main renal lesion. For assessment of the therapeutic response, RECIST 1.1 is used. Partial response (PR), stable disease (SD) and progressive disease (PD) were observed in 12 (37.50%), 10 (31.25%) and 10 (31.25%) cases with mean TTP of 10.33 ± 2.06 months (95% confidence interval, CI = 9.05-11.61), 7.40 ± 2.50 months (95% CI = 5.61-9.19) and 4.20 ± 1.99 months (95% CI = 2.78-5.62) accordingly (p < 0.05). There was no difference in change of main lesions' longest size 1 month after ST in patients with PR, SD and PD. Comparison of mean ADC values before and 1 month after systemic treatment showed significant decrease by 19.11 ± 10.64% (95% CI = 12.35-25.87) and by 7.66 ± 6.72% (95% CI = 2.86-12.47) in subgroups with PR and SD, respectively (p < 0.05). There was shorter TTP in patients with mRCC if ADC of the main renal lesion 1 month after the ST increased from the baseline less than 1.73% compared to patients with ADC levels above this threshold: 5.29 ± 3.45 versus 9.50 ± 2.04 months accordingly (p < 0.001). Overall, our findings highlighted the use of ADC as a predictive biomarker for early therapeutic response assessment. Use of ADC will be effective and useful for reliable prediction of responders and non-responders to systemic treatment with pazopanib.
Department of Internal Medicine Brothers of Mercy Hospital Polni 553 3 63900 Brno Czech Republic
Department of Postgraduate Education and Research Kazakhstan Medical University Almaty Kazakhstan
Department of Radiology Lviv National Medical University n a Danylo Halytsky Lviv Ukraine
Department of Urology Centre of Postgraduate Medical Education Warsaw Poland
Faculty of Health and Social Work Trnava University Trnava Slovakia
Zobrazit více v PubMed
Clin Exp Med. 2019 Feb;19(1):143-148 PubMed
Cancer Biol Ther. 2010 Jan;9(1):15-9 PubMed
Int Urol Nephrol. 2017 Feb;49(2):215-224 PubMed
AJR Am J Roentgenol. 2016 Jan;206(1):100-5 PubMed
Int J Epidemiol. 2019 Dec 1;48(6):1886-1896 PubMed
Oncologist. 2014 May;19(5):507-14 PubMed
Semin Roentgenol. 2014 Jul;49(3):238-41 PubMed
BMC Cancer. 2017 Jun 2;17(1):392 PubMed
N Engl J Med. 2017 Jan 26;376(4):354-366 PubMed
Contrast Media Mol Imaging. 2017 Apr 9;2017:7498538 PubMed
Radiology. 2017 Apr;283(1):168-177 PubMed
Clin Med Insights Oncol. 2011;5:333-42 PubMed
Curr Opin Urol. 2018 Jan;28(1):35-41 PubMed
Clin Exp Med. 2018 May;18(2):165-175 PubMed
Cancer Res. 2017 Aug 1;77(15):4127-4134 PubMed
Br J Radiol. 2015 Sep;88(1053):20150163 PubMed
Clin Radiol. 2018 Sep;73(9):832.e9-832.e16 PubMed
J Nucl Med. 2009 May;50 Suppl 1:122S-50S PubMed
Transl Oncol. 2016 Apr;9(2):155-162 PubMed
Pol J Radiol. 2014 Sep 01;79:290-5 PubMed
Br J Cancer. 2014 Feb 4;110(3):616-24 PubMed
J Comput Assist Tomogr. 2019 May/Jun;43(3):493-498 PubMed
Cancer Biol Ther. 2010 Jan;9(1):20-2 PubMed
Cell Mol Biol (Noisy-le-grand). 2016 Dec 30;62(14):64-68 PubMed
Lancet Oncol. 2013 Feb;14(2):141-8 PubMed
PLoS One. 2017 Sep 8;12(9):e0184423 PubMed
Clin Exp Med. 2019 Nov;19(4):515-524 PubMed
Cell Biochem Funct. 2015 Jul;33(5):257-65 PubMed
Int Urol Nephrol. 2018 Feb;50(2):197-204 PubMed
Oncotarget. 2017 Sep 16;8(49):86157-86167 PubMed
